Remicade Biosimilar Market Report 2025

The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.95 billion in 2024 to $4.93 billion in 2025 at a compound annual growth rate (CAGR) of 24.9%. The growth in the historic period can be attributed to the introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, and healthcare cost pressures.

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $11.07 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.

The increasing incidence of autoimmune diseases is anticipated to drive the growth of the remicade biosimilar market in the future. Autoimmune diseases are conditions where the immune system erroneously attacks and damages the body’s tissues and organs. Remicade biosimilars are utilized in treating autoimmune diseases by offering an effective therapeutic option to manage symptoms and reduce inflammation. For example, in July 2023, data from Public Health Scotland, a national organization in Scotland, indicated that in 2022, the number of newly diagnosed patients with multiple sclerosis (MS) rose to 87.2%, up from 85.7% in 2020, with 491 new cases reported, resulting in a total of 6,359 cases in 2022. Thus, the increasing incidence of autoimmune diseases is propelling the growth of the remicade biosimilar market.

The growing healthcare expenditure is significantly impacting the growth of the remicade biosimilar market in the coming years. Healthcare expenditure refers to the total amount spent on healthcare goods and services within a specific timeframe, typically on an annual basis. Biologic drugs, such as Remicade, are often costly. As healthcare spending increases, there is a heightened focus on cost containment and the more efficient allocation of resources. Biosimilars provide a more economical alternative to their originator biologics, including Remicade. For instance, in October 2024, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that prescription drug spending grew by 8.4%, reaching $405.9 billion in 2022, surpassing the 6.8% growth recorded in 2021. Therefore, the rising healthcare expenditure is expected to drive the remicade biosimilar market.

Innovation in product development is a notable trend in the Remicade biosimilar market, with major companies focusing on introducing innovative products to maintain their market position. An example is Amgen Inc., a US-based biotechnology company, which launched Amjevita in January 2023. Amjevita is a biosimilar version of AbbVie's Humira, designed to be as safe and effective as the original drug. With a lower cost than Humira, Amjevita offers patients a more affordable treatment option for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Major companies in the remicade biosimilar market are concentrating on creating innovative solutions, such as subcutaneous formulations, to achieve a competitive edge. Subcutaneous formulations of Remicade offer an alternative method of administration for treating autoimmune diseases, enabling self-administration and potentially enhancing patient adherence to therapy. For example, in March 2024, Celltrion, a biopharmaceutical company based in South Korea, introduced Zymfentra, a biosimilar to Remicade (infliximab), priced at $6,181.08 for two doses over four weeks. This formulation received FDA approval as the first subcutaneous infliximab option for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn's disease. Eligible patients with commercial insurance can access copay assistance of $5 per month, while uninsured or underinsured individuals may receive Zymfentra at no cost.

In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsung Bioepis Co. Ltd. for $2.3 billion. This acquisition positions Samsung Biologics to meet the increasing demand for biosimilars, access a broader range of products, expand manufacturing capacity, and strengthen its global reach. Samsung Bioepis Co. Ltd. is a South Korea-based biopharmaceutical company specializing in producing Remicade biosimilar products.

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A.

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the remicade biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A Remicade biosimilar is a biological drug that is similar to Remicade, and it is utilized in the treatment of certain autoimmune diseases in both adults and children. This type of medication is specifically designed to address autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

The main types of biosimilars in the Remicade biosimilars category come in strengths of 100 mg/10 ml and 500 mg/50 ml. The 100 mg/10 ml strength indicates the amount of drug in the dosage form or a unit of the dosage form, equivalent to 100 mg per 10 ml. The applications for these biosimilars include the treatment of conditions such as ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, and plaque psoriasis. Additionally, they are used for various applications in the treatment of blood disorders and oncology diseases.

The remicade biosimilars market research report is one of a series of new reports that provides remicade biosimilars market statistics, including remicade biosimilars industry global market size, regional shares, competitors with a remicade biosimilars market share, detailed remicade biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the remicade biosimilars industry. This remicade biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade biosimilar market consists of sales of inflectra, renflexis, avolsa, remsima, infimab, and avolsa. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.